BioVie Inc. (BIVI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BIVI
- Company BioVie Inc.
- Price $1.93
- Changes Percentage 1.05
- Change 0.02
- Day Low $1.92
- Day High $2.02
- Year High $3.79
- Year Low $0.82
- Market Cap $14,707,559
- Price Avg 50 EMA (D) $1.66
- Price Avg 200 EMA (D) $1.46
- Exchange NASDAQ
- Volume 19,611,346
- Average Volume 4,577,890
- Open $1.94
- Previous Close $1.91
- EPS -3.15
- PE -0.62
- Earnings Announcement 2026-12-02 12:00:00
- Shares Outstanding $7,542,338
Company brief: BIOVIE INC. (BIVI )
- Healthcare
- Biotechnology
- Mr. Cuong Viet Do M.B.A.
- https://bioviepharma.com
- US
- N/A
- 09-18-2020
- US09074F2074
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.